| Prerestriction Year 2012 | Restriction Year 2013 | Postrestriction Year 2014 | |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| OER patients in study-MAPD, n | 2,248 | 2,935 | 2,222 |
| ≥ 1 claim (OER or LAO) in postperiod | |||
| Disenrolled | 289 | 162 | 318 |
| ≥ 1 OER claim postrestriction | 209 (72.3) | 97 (59.9) | 222 (69.8) |
| Switched to other LAO | 16 (5.5) | 18 (11.1) | 29 (9.1) |
| Discontinued all LAO | 64 (22.1) | 47 (29.0) | 67 (21.1) |
| Remained | 1,959 | 2,773 | 1,904 |
| ≥ 1 OER claim postrestriction | 1,576 (80.4) | 1,659 (59.8) | 1,473 (77.4) |
| Switched to other LAO | 86 (4.4) | 642 (23.2) | 183 (9.6) |
| Discontinued all LAO | 297 (15.2) | 472 (17.0) | 248 (13.0) |
| ≥ 2 claims (OER or LAO) in postperiod | |||
| Disenrolled | 289 | 162 | 318 |
| Continued with ≥ 2 OER claims | 182 (63.0) | 80 (49.4) | 182 (57.2) |
| Switched to other LAO (≥ 2 other LAO claims) | 11 (3.8) | 17 (10.5) | 23 (7.2) |
| Discontinued all LAOs | 64 (22.1) | 47 (29.0) | 67 (21.1) |
| Other (< 2 OER or LAO claims) | 32 (11.1) | 18 (11.1) | 46 (14.5) |
| Remained | 1,959 | 2,773 | 1,904 |
| ≥ 2 OER claims postrestriction | 1,455 (74.3) | 1,252 (45.1) | 1,264 (66.4) |
| Switched to other LAO | 69 (3.5) | 561 (20.2) | 156 (8.2) |
| Discontinued all LAO | 297 (15.2) | 472 (17.0) | 248 (13.0) |
| Other (< 2 OER or LAO claims) | 138 (7.0) | 488 (17.6) | 236 (12.4) |
LAO = long-acting opioid; MAPD = Medicare Advantage prescription drug plan; OER = oxycodone HCl extended-release.